Induction of unresponsiveness to islet xenografts by a short-course treatment by anti-CD4 nondepleting monoclonal antibody.
Lu
X
X
Novartis Pharma Inc., Transplantation Department, Basel, Switzerland.
Schulz
M
M
Zihlmann
H R
HR
Borel
J F
JF
D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000276:immunology*; D015704:CD4 Antigens / Q000276:immunology*; D006224:Cricetinae; D003921:Diabetes Mellitus, Experimental / Q000276:immunology / Q000601:surgery*; D006084:Graft Rejection / Q000276:immunology* / Q000517:prevention & control; D006085:Graft Survival / Q000276:immunology*; D007108:Immune Tolerance; D016381:Islets of Langerhans Transplantation / Q000276:immunology*; D008297:Male; D051379:Mice; D008808:Mice, Inbred CBA; D014183:Transplantation, Heterologous
D000911:Antibodies, Monoclonal; D015704:CD4 Antigens